MindMed

MindMed is in the running for a panel at SXSW 2025, and we need your support! Anxiety is a growing burden and many patients are underserved. Our panel, "Understanding Anxiety Inside Out – Beyond the Emotions," will take inspiration from the beloved movie Inside Out 2 to explore the complexities of anxiety from a whole new perspective. We will explore the broader implications of anxiety disorders, as well as the latest developments in anxiety treatments, uncovering innovative solutions and addressing ongoing unmet medical needs in mental health. 🗳️ Every vote counts, so please take a moment to cast yours before the deadline on Sunday, August 18th. Vote here: https://lnkd.in/gYZuXyHm

We're excited to announce that MindMed will be participating in the upcoming Canaccord Genuity Group Inc. Conference! This prestigious annual event brings together institutional investors from around the world. We're delighted to share with them our insights about the significant unmet needs in treating Generalized Anxiety Disorder and our vision for the potential of MM120, our lead product which will be entering Phase III clinical trials later this year. We look forward to connecting with industry leaders and investors to discuss our latest advancements and our commitment to shaping the future of mental health.

Join us on August 13, 2024, at 8:00 AM ET for our quarterly earnings conference call where we will discuss our Q2 2024 financial results and provide business updates. Register here: https://lnkd.in/eDqZXCPR Read the full press release here: https://lnkd.in/eXZEpDxn

"Our mission at MindMed is to push the boundaries of mental health treatment. We believe in the potential of psychedelics to transform lives and bring hope to those with GAD." - Robert Barrow, CEO of MindMed At MindMed, we're dedicated to revolutionizing mental health care through cutting-edge research and development. Our team is focused on creating innovative, science-backed treatments to improve the lives of those with Generalized Anxiety Disorder (GAD). By harnessing the therapeutic potential of psychedelics, we aim to address not just symptoms, but the root causes of mental health conditions. Our holistic approach strives to offer patients a better quality of life, free from the constraints of traditional medications.

“MindMed is pioneering the future of brain health with potential groundbreaking treatments, and I am thrilled to join a company dedicated to transforming patient outcomes in an area of immense public health need,” - Stephanie Fagan, newly appointed Chief Corporate Affairs Officer of MindMed We’re excited to welcome Stephanie Fagan to the MindMed team, as Chief Corporate Affairs Officer. With over 20 years of experience as an executive in the healthcare industry, Ms. Fagan will serve as an executive team member, overseeing public affairs and corporate communications.

1̳9̳5̳0̳-̳1̳9̳6̳0̳ Psychedelic research blossomed to reveal innovative approaches to treatments, showing the potential of psychedelics to enhance emotional insight and facilitate profound psychological breakthroughs. As we build upon this rich history, we're working to shape a brighter future for mental health care, with innovative treatments that offer hope to individuals suffering from mental health issues. #psychedelics #MentalHealth

Time for the poll results! If you guessed "All of the above", you're correct! GAD can manifest in many ways that might seem unrelated at first. If you're experiencing any of these symptoms, it might be time to reach out to a mental healthcare professional: - Excessive worry - Restlessness - Fatigue - Upset stomach, stomach pains and/or nausea - Difficulty concentrating - Irritability - Muscle tension - Sleep disturbances, like trouble falling or staying asleep Remember, GAD is a common condition and early intervention can significantly improve your quality of life. Don't hesitate to seek professional help if you recognize these signs in yourself or a loved one.

An exciting day for us at MindMed! We're thrilled to announce the issuance of a new patent covering the pharmaceutical formulation for our MM120 Orally Disintegrating Tablet (ODT). This patent extends our IP protection for MM120 through 2041 and covers the unique properties of our MM120 ODT formulation. Stay tuned for updates as we advance into Phase III! Read the full Press Release here: https://lnkd.in/d26kkmUW

According to Psychology Today, 30% of adults in North America experience anxiety, but only a third of them are properly diagnosed. This means nearly 10% of the adult population may have undiagnosed or misdiagnosed anxiety issues. Raising awareness and improving diagnosis is crucial for better mental health care. So, how well do you know GAD? Answer our poll below - and check back next week to find out the answer!

Psychedelic research is moving at an outstanding pace - and sometimes it's hard to keep up! Our CMO, Dan Karlin answers questions such as, "What is FDA breakthrough designation?" and more. Watch the video here: https://lnkd.in/ekYVEVfW